Clinical Trial VICCPHI1314


A Phase I/II Study of Once or Twice Weekly IMMU-130 (hMN-14- SN38, Antibody-Drug Conjugate) in Patients with Colorectal Cancer

Principal Investigator(s)

Jordan Berlin


  • Protocol No. VICCPHI1314
  • Open Date: 06/25/2013
  • Staging: Phase I/II
  • Age Group: Adults
  • Scope: National
  • Objective: To evaluate the safety and tolerability of repeated 21-day treatment cycles of IMMU-130 and to determine the maximum tolerated dose (MTD) for this dosing schedule when administered to patients with metastatic colorectal cancer who have failed at least one prior irinotecan-containing therapy.
  • Disease Sites:
  • Therapies: Molecular Targeted Agents / Immunotherapy / Biologics
  • Drugs: None Specified
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01605318
  • Secondary Protocol No: IMMU-130-02



Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.